SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ:BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the appointment of Stephen Gould, Ph.D., as Chief Scientific Officer.
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
Globe Newswire - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Blackrock%20Inc_%20logo%20on%20building-%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/2d%20illustration%20of%20Cloud%20computing%20by%20Blackboard%20via%20Shutterstock.jpg)
/Amazon_com%20Inc_%20storefront%20by-%20%20Markus%20Mainka%20via%20Shutterstock.jpg)